Table 1 Baseline characteristics of study population, n (%)
Total (n = 14,505) | De novo patients (n = 12,811) | Relapsed/progressed patients (n = 1,694) | ||
|---|---|---|---|---|
Age group at initiation of first-line therapy, years | ||||
< 60 | 2,682 (18.5) | 2,354 (18.4) | 328 (19.4) | |
60–69 | 5,269 (36.3) | 4,578 (35.7) | 691 (40.8) | |
70–79 | 5,499 (37.9) | 4,894 (38.2) | 605 (35.7) | |
≥ 80 | 1,055 (7.3) | 985 (7.7) | 70 (4.1) | |
Sex | ||||
Male | 12,633 (87.1) | 11,160 (87.1) | 1,473 (87.0) | |
Female | 1,872 (12.9) | 1,651 (12.9) | 221 (13.1) | |
CCI | ||||
< 3 | 9,290 (64.1) | 8,225 (64.2) | 1,065 (62.9) | |
≥ 3 | 5,215 (36.0) | 4,586 (35.8) | 629 (37.1) | |
Insurance type | ||||
National health insurance | 13,479 (92.9) | 11,907 (92.9) | 1,572 (92.8) | |
Medical aid or veterans | 1,026 (7.1) | 904 (7.1) | 122 (7.2) | |
Type of hospital at initiation of first-line therapy | ||||
Tertiary hospital | 10,512 (72.5) | 9,251 (72.2) | 1,261 (74.4) | |
Others | 3,993 (27.5) | 3,560 (27.8) | 433 (25.6) | |
Geographic region of hospital | ||||
Capital area | 9,408 (64.9) | 8,220 (64.2) | 1,188 (70.1) | |
Metropolitans | 2,753 (19.0) | 2,477 (19.3) | 276 (16.3) | |
Rural | 2,344 (16.2) | 2,114 (16.5) | 230 (13.6) | |
Time point at initiation of first-line therapy | ||||
Pre-immunotherapy era | 8,117 (56.0) | 7,194 (56.2) | 923 (54.5) | |
Post-immunotherapy era | 6,388 (44.0) | 5,617 (43.9) | 771 (45.5) | |